Penelope Drake

· Appointed Interim Co GM to lead orderly site wind down while simultaneously retaining Head of R&D accountability, ensuring business continuity, people stewardship, and asset value preservation · Partnered with corporate leadership to define shutdown strategy, including R&D resourcing plans, knowledge retention, and technology transfer of critical capabilities to other Catalent sites · Designed and championed a pragmatic, cost conscious intellectual property (IP) strategy offering continuity and ongoing monetizing opportunities

· R&D site head: built, led, and scaled a high performing, multidisciplinary R&D organization · Core business development leader, with extensive experience interfacing with VCs and strategic partners · Played a central role in securing and executing the Exelixis partnership, serving as primary scientific liaison and Joint Steering Committee member and helping establish a high trust, long term collaboration · Directly led the design and execution of the first two joint Exelixis ADC discovery programs from inception through development candidate nomination; both programs (XB010, XB371) now in Phase 1 clinical trials · Led scientific vision and execution for the SMARTag® bioconjugation platform, driving sustained innovation across dual payload and next generation linker payload technologies · Defined translational, clinical, and regulatory strategy for a MUC1 ADC program, leveraging PDX mouse clinical trials to prioritize platinum resistant ovarian cancer; drove FDA Type D engagement, competitive landscape assessment, and IND readiness planning using both internal talent and external consultants · Owned IP portfolio strategy, partnering with counsel to shape patent filings and prosecution aligned with platform evolution, partnering strategy, and long term enterprise value · Elevated platform visibility and external validation, with SMARTag® recognized as Runner Up, Best ADC Platform at World ADC for three consecutive years (2022–2024) · Envisioned and led a major site reorganization, unlocking internal leadership talent and establishing a new Project Management function; doubled productivity and enabled expansion of partner programs and internal innovation without added headcount · Recognized for people first leadership, driving high engagement and low attrition through transparent communication, talent development, and individualized coaching

• Key driver of technical transfer for TRPH-222 asset to Triphase Accelerator Corp. after licensing. Prepared IND-ready reports documenting preclinical results. Only permanent Catalent member of the PharmTox team responsible for IND-enabling studies. TRPH-222 began Phase I dosing in 2019. • Spearheaded development of preclinical data package that resulted in the 2016 Triphase acquisition of the SMARTag® αCD22 ADC. • Design and implement strategies for new asset development, including short-term and mid-term opportunities for pipeline growth. • Direct the chemistry, protein production, and bioconjugation/analytical teams.

Catalent Pharma Solutions, Emeryville, CA Biology Group Leader October 2014–present (retained after Catalent acquisition of Redwood Bioscience) • Recruited and guided the analytical chemistry team that provided LC/MS-based analyses at the small molecule, protein, and ADC levels in support of the chemistry and bioconjugation teams. • Orchestrated the design, outsourcing, and analysis of preclinical in vivo studies; oversaw CRO partnerships. • Developed and executed ligand-binding and LC/MS-based assays for PK/TK analyses.

Redwood Bioscience, Emeryville, CA ` 2011– 2014 Biology Group Leader 2013–2014 • Championed the Technical Proof-of-Concept package for the Catalent acquisition (generated critical data, wrote the report, presented the oral defense to the board). • Mobilized and united teams to ensure that goals and timelines were met in a fast-paced environment as company-size doubled prior to the Catalent acquisition. • Interfaced with pharma partners to discuss data, project goals, and develop appropriate analytics. • Performed the ex-vivo portion of all in-house and pharma partner PK/TK studies (50+ experiments). • Key player in designing, overseeing, and executing preclinical studies and accompanying analytics for in-house ADC programs. • Managed work with a variety of CROs for outsourcing of experiments, analytics, and reagent development.

Redwood Bioscience, Emeryville, CA ` 2011– 2014 Senior Research Scientist–Analytical Chemist 2011–2013 • Established the analytical department to provide comprehensive in-house mass spectrometric-based analytical support—including intact protein, peptide, and small molecule studies—for biology and chemistry teams. • Operated and maintained an ABSciex 4000 QTRAP mass spectrometer with in-line Eksigent nanoLC system. • Designed and oversaw outsourced in vitro and in vivo biological assays and antibody development.

UCSF Sandler-Moore Mass Spectrometry Core Facility, San Francisco, CA Core Facility Manager–Assistant Researcher 2010–2011 • Managed contract research projects with core facility clients; identified mass spectrometric-based solutions to experimental needs; delivered results on schedule; monitored billing for services. • Led a three-lab study to find breast cancer subtype-specific biomarkers using lectin chromatography-based discovery and multi-reaction monitoring (MRM)-based verification. • Wrote and edited grants, manuscripts, progress reports, and other scientific documents.

UCSF Sandler-Moore Mass Spectrometry Core Facility, San Francisco, CA Associate Specialist 2007–2010 • Led a two-lab effort to develop a lectin chromatography workflow to select alternatively glycosylated plasma proteins as early biomarkers for breast cancer. • Led a three-lab, multi-dimensional effort to refine the human salivary proteome. • Determined the sulfation patterns on glycans isolated from human saliva.

Advisor: Prof. Carolyn Bertozzi •Established an immunological role for the well-known “neurological” glycan, polysialic acid. •Demonstrated that this post-translational modification affects T-cell development by modulating hematopoietic progenitor trafficking.

Advisor: Prof. Susan Fisher Thesis title: Chemokine expression and function at the human maternal-fetal interface. •Revealed the abundant expression of numerous chemokines on both sides of the maternal-fetal interface during human pregnancy. •Showed that placental cells produce CCL3 (MIP-1α) and thereby recruit monocytes and CD56bright natural killer cells, leukocyte populations that are hallmarks of the pregnant uterus.